

GENOMIC HEALTH INC  
Form SC 13D/A  
April 12, 2019

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13D  
Under the Securities Exchange Act of 1934

(Amendment No. 41)

**Genomic Health, Inc.**  
(Name of Issuer)

**Common Stock, par  
value \$0.0001 per  
share**  
(Title of Class of  
Securities)

**37244C101**  
(CUSIP  
Number)

Alexandra A. Toohey  
Chief Financial Officer

Baker Bros. Advisors  
LP

860 Washington Street,  
3<sup>rd</sup> Floor

New York, NY 10014

(212) 339-5690

(Name, address and  
telephone number of  
person authorized to  
receive notices and  
communications)

**April 10,  
2019**  
(Date of  
Event  
which  
Requires  
Filing of  
this  
Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. "

**Note:** Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 37244C101 Page 2 of 13 Pages

NAMES OF REPORTING  
PERSONS

1

Baker Bros. Advisors LP

2

CHECK THE  
APPROPRIATE (a) ..

BOX IF A  
MEMBER OF A (b) ..

GROUP (See  
Instructions)

3

SEC USE ONLY

SOURCE OF FUNDS (See  
Instructions)

4

OO

5

CHECK BOX  
IF  
DISCLOSURE  
OF LEGAL  
PROCEEDINGS

IS REQUIRED  
PURSUANT TO  
ITEMS 2(d) OR  
2(e)

CITIZENSHIP OR PLACE  
OF ORGANIZATION

6

Delaware

NUMBER OF  
SHARES  
BENEFICIALLY  
OWNED BY  
EACH  
REPORTING

7

SOLE  
VOTING  
POWER

**PERSON  
WITH**

9,421,702 (1)

SHARED  
VOTING  
POWER

**8**

0

SOLE  
DISPOSITIVE  
POWER

**9**

9,421,702 (1)

**10** SHARED  
DISPOSITIVE  
POWER

0

AGGREGATE AMOUNT  
BENEFICIALLY OWNED  
BY EACH REPORTING  
PERSON

**11**

9,421,702 (1)

**12**

CHECK BOX IF  
THE AGGREGATE  
AMOUNT IN ROW  
(11) EXCLUDES  
CERTAIN  
SHARES (See  
Instructions)

**13**

PERCENT OF CLASS  
REPRESENTED BY  
AMOUNT IN ROW (11)

25.4% (1)(2)

TYPE OF REPORTING  
PERSON (See Instructions)

14

IA, PN

Includes 84,515 shares of the common stock of Genomic Health, Inc. (the "Issuer") underlying options directly held by Julian C. Baker, 76,265 shares of the Issuer's common stock underlying options directly held by Felix J. Baker, (1) 40,811 shares of the Issuer's common stock directly held by Julian C. Baker and 8,466 shares of the Issuer's common stock directly held by Felix J. Baker.

(2) Based on 36,904,013 shares of the Issuer's common stock outstanding as of February 22, 2019, as reported in the Issuer's Form 10-K filed with the Securities and Exchange Commission ("SEC") on February 28, 2019.

Page 2 of 13 Pages



**PERSON  
WITH**

9,421,702 (1)

SHARED  
VOTING  
POWER

**8**

0

SOLE  
DISPOSITIVE  
POWER

**9**

9,421,702 (1)

**10** SHARED  
DISPOSITIVE  
POWER

0

AGGREGATE AMOUNT  
BENEFICIALLY OWNED  
BY EACH REPORTING  
PERSON

**11**

9,421,702 (1)

**12**

CHECK BOX IF THE  
AGGREGATE  
AMOUNT IN ROW ..  
(11) EXCLUDES  
CERTAIN SHARES  
(See Instructions)

**13**

PERCENT OF CLASS  
REPRESENTED BY  
AMOUNT IN ROW (11)

25.4% (1)(2)

TYPE OF REPORTING  
PERSON (See Instructions)

**14**

HC, OO

Includes 84,515 shares of the common stock of the Issuer underlying options directly held by Julian C. Baker,  
(1) 76,265 shares of the Issuer's common stock underlying options directly held by Felix J. Baker, 40,811 shares of the  
Issuer's common stock directly held by Julian C. Baker and 8,466 shares of the Issuer's common stock directly held  
by Felix J. Baker.

(2) Based on 36,904,013 shares of the Issuer's common stock outstanding as of February 22, 2019, as reported in the  
Issuer's Form 10-K filed with the SEC on February 28, 2019.

Page 3 of 13 Pages



CUSIP No. 37244C101 Page 4 of 13 Pages

NAMES OF REPORTING  
PERSONS

1

Julian C. Baker

2

CHECK THE  
APPROPRIATE (a) ..

BOX IF A  
MEMBER OF A (b) ..

GROUP (See  
Instructions)

3

SEC USE ONLY  
SOURCE OF FUNDS (See  
Instructions)

4

OO

5

CHECK BOX  
IF  
DISCLOSURE  
OF LEGAL  
PROCEEDINGS  
IS REQUIRED  
PURSUANT TO  
ITEMS 2(d) OR  
2(e)  
CITIZENSHIP OR PLACE  
OF ORGANIZATION

6

United States

NUMBER OF  
SHARES  
BENEFICIALLY  
OWNED BY  
EACH  
REPORTING

7

SOLE  
VOTING  
POWER

**PERSON  
WITH**

9,595,599 (1)

SHARED  
VOTING  
POWER

**8**

0

SOLE  
DISPOSITIVE  
POWER

**9**

9,595,599 (1)

**10** SHARED  
DISPOSITIVE  
POWER

0

AGGREGATE AMOUNT  
BENEFICIALLY OWNED  
BY EACH REPORTING  
PERSON

**11**

9,595,599 (1)

**12**

CHECK BOX IF  
THE AGGREGATE  
AMOUNT IN ROW  
(11) EXCLUDES  
CERTAIN  
SHARES (See  
Instructions)

**13**

PERCENT OF CLASS  
REPRESENTED BY  
AMOUNT IN ROW (11)

25.9% (1)(2)

TYPE OF REPORTING  
PERSON (See Instructions)

14

IN, HC

- Includes 84,515 shares of the common stock of the Issuer underlying options directly held by Julian C. Baker, 76,265 shares of the Issuer's common stock underlying options directly held by Felix J. Baker, 40,811 shares of the Issuer's common stock directly held by Julian C. Baker and 8,466 shares of the Issuer's common stock directly held by Felix J. Baker.
- (1)
- (2) Based on 36,904,013 shares of the Issuer's common stock outstanding as of February 22, 2019, as reported in the Issuer's Form 10-K filed with the SEC on February 28, 2019.

Page 4 of 13 Pages

CUSIP No. 37244C101 Page 5 of 13 Pages

NAMES OF REPORTING  
PERSONS

1

Felix J. Baker

2

CHECK THE  
APPROPRIATE (a) ..

BOX IF A  
MEMBER OF A (b) ..

GROUP (See  
Instructions)

3

SEC USE ONLY  
SOURCE OF FUNDS (See  
Instructions)

4

OO

5

CHECK BOX  
IF  
DISCLOSURE  
OF LEGAL  
PROCEEDINGS  
IS REQUIRED  
PURSUANT TO  
ITEMS 2(d) OR  
2(e)  
CITIZENSHIP OR PLACE  
OF ORGANIZATION

6

United States

NUMBER OF  
SHARES  
BENEFICIALLY  
OWNED BY  
EACH  
REPORTING

7

SOLE  
VOTING  
POWER

**PERSON  
WITH**

9,595,599 (1)

SHARED  
VOTING  
POWER

**8**

0

SOLE  
DISPOSITIVE  
POWER

**9**

9,595,599 (1)

**10** SHARED  
DISPOSITIVE  
POWER

0

AGGREGATE AMOUNT  
BENEFICIALLY OWNED  
BY EACH REPORTING  
PERSON

**11**

9,595,599 (1)

**12**

CHECK BOX IF  
THE AGGREGATE  
AMOUNT IN ROW  
(11) EXCLUDES  
CERTAIN  
SHARES (See  
Instructions)

**13**

PERCENT OF CLASS  
REPRESENTED BY  
AMOUNT IN ROW (11)

25.9% (1)(2)

TYPE OF REPORTING  
PERSON (See Instructions)

14

IN, HC

- Includes 84,515 shares of the common stock of the Issuer underlying options directly held by Julian C. Baker, 76,265 shares of the Issuer's common stock underlying options directly held by Felix J. Baker, 40,811 shares of the Issuer's common stock directly held by Julian C. Baker and 8,466 shares of the Issuer's common stock directly held by Felix J. Baker.
- (1)
- (2) Based on 36,904,013 shares of the Issuer's common stock outstanding as of February 22, 2019, as reported in the Issuer's Form 10-K filed with the SEC on February 28, 2019.

CUSIP No. 37244C101 Page 6 of 13 Pages

NAMES OF REPORTING  
PERSONS

1

FBB Associates

2

CHECK THE  
APPROPRIATE (a) ..

BOX IF A  
MEMBER OF A (b) ..

GROUP (See  
Instructions)

3

SEC USE ONLY  
SOURCE OF FUNDS (See  
Instructions)

4

OO

5

CHECK BOX  
IF  
DISCLOSURE  
OF LEGAL  
PROCEEDINGS  
IS REQUIRED  
PURSUANT TO  
ITEMS 2(d) OR  
2(e)  
CITIZENSHIP OR PLACE  
OF ORGANIZATION

6

New York

NUMBER OF  
SHARES  
BENEFICIALLY  
OWNED BY  
EACH  
REPORTING

7

SOLE  
VOTING  
POWER

**PERSON  
WITH**

173,897

SHARED  
VOTING  
POWER

**8**

0

SOLE  
DISPOSITIVE  
POWER

**9**

173,897

**10** SHARED  
DISPOSITIVE  
POWER

0

AGGREGATE AMOUNT  
BENEFICIALLY OWNED  
BY EACH REPORTING  
PERSON

**11**

173,897

**12**

CHECK BOX IF  
THE AGGREGATE  
AMOUNT IN ROW  
(11) EXCLUDES  
CERTAIN  
SHARES (See  
Instructions)

**13**

PERCENT OF CLASS  
REPRESENTED BY  
AMOUNT IN ROW (11)



0.5% (1)

TYPE OF REPORTING  
PERSON (See Instructions)

**14**

OO

(1) Based on 36,904,013 shares of the Issuer's common stock outstanding as of February 22, 2019, as reported in the Issuer's Form 10-K filed with the SEC on February 28, 2019.

Page 6 of 13 Pages

### **Amendment No. 41 to Schedule 13D**

This Amendment No. 41 to Schedule 13D amends and supplements the statements on the previously filed Schedule 13D, as amended, filed by Baker Bros. Advisors LP (the “Adviser”), Baker Bros. Advisors (GP) LLC (the “Adviser GP”), Julian C. Baker, Felix J. Baker, and FBB Associates (“FBB”) collectively, (the “Reporting Persons”). Except as supplemented herein, such statements, as hereto amended and supplemented, remain in full force and effect. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Each capitalized term used but not defined herein has the meaning ascribed to such term in the Schedule 13D, as amended.

The Adviser GP is the sole general partner of the Adviser. Pursuant to the management agreements, as amended, among the Adviser, Baker Brothers Life Sciences, L.P. (“Life Sciences”), 14159, L.P. (“14159”), 667, L.P. (“667”), Baker Bros. Investments, L.P. (“Baker Bros. Investments”), Baker Bros. Investments II, L.P. (“Baker Bros. Investments II”), and Baker/Tisch Investments, L.P. (“Baker Tisch”, and together with Life Sciences, 14159, 667, Baker Bros. Investments and Baker Bros. Investments II, the “Funds”), and their respective general partners, the Funds’ respective general partners relinquished to the Adviser all discretion and authority with respect to the investment and voting power of securities held by the Funds, and thus the Adviser has complete and unlimited discretion and authority with respect to the Funds’ investments and voting power over investments.

### **Item 3. Source and Amount of Funds or Other Consideration**

Item 3 of Schedule 13D is supplemented and amended, as the case may be, as follows:

The disclosure in Item 4 below is incorporated herein by reference.

### **Item 4. Purpose of the Transaction.**

Item 4 of Schedule 13D is supplemented and amended, as the case may be, as follows:

This Amendment No. 41 is being filed to report the sale of shares of the common stock of Genomic Health, Inc. (the “Issuer”) reported in Item 5(c) that resulted in a more than 1 percent change in beneficial ownership. The disclosure regarding the sales in Item 5(c) below is incorporated herein by reference.

The Funds hold securities of the Issuer for investment purposes. The Reporting Persons or their affiliates may dispose of additional securities of the Issuer or purchase securities in varying amounts and at varying times depending upon the Reporting Persons' continuing assessments of pertinent factors, including the availability of shares of common stock or other securities for purchase at particular price levels, the business prospects of the Issuer, other business investment opportunities, economic conditions, stock market conditions, money market conditions, the attitudes and actions of the Board and management of the Issuer, the availability and nature of opportunities to dispose of shares of the Issuer and other plans and requirements of the particular entities. The Reporting Persons may discuss items of mutual interest with the Issuer, which could include items in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

Depending upon their assessments of the above factors, the Reporting Persons or their affiliates may change their present intentions as stated above and they may make suggestions to the management of the Issuer regarding financing, and may acquire additional securities of the Issuer, including shares of common stock (by means of open market purchases, privately negotiated purchases, exercise of some or all of the Stock Options (as defined below), or otherwise) or may dispose of some or all of the securities of the Issuer, including shares of common stock, under their control.

Except as otherwise disclosed herein, at the present time, the Reporting Persons do not have any plans or proposals with respect to any extraordinary corporate transaction involving the Issuer including, without limitation, those matters described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

**Item 5. Interest in Securities of the Issuer.**

Item 5 of this Schedule 13D is hereby amended and restated in its entirety as follows:

(a) and (b) Items 7 through 11 and 13 of each of the cover pages of this Amendment No. 41 are incorporated herein by reference. Set forth below is the aggregate number of shares of common stock of the Issuer directly held by each of the Funds and the percentage of the Issuer's outstanding shares of common stock such holdings represent. The information set forth below is based upon 36,904,013 shares of common stock outstanding as of February 22, 2019, as reported in the Issuer's Form 10-K filed with the SEC on February 28, 2019. Such percentage figures are calculated in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended.

Name	Number of Shares	Percentage of Class Outstanding	
Baker Bros. Investments, L.P.	116,492	0.3	%
Baker Bros. Investments II, L.P.	8,866	0.0	%
667, L.P.	1,165,298	3.2	%
Baker Brothers Life Sciences, L.P.	7,590,061	20.6	%
14159, L.P.	200,864	0.5	%
Baker/Tisch Investments, L.P.	130,064	0.4	%

The Adviser GP, Felix J. Baker and Julian C. Baker as managing members of the Adviser GP, and the Adviser may be deemed to be beneficial owners of securities of the Issuer directly held by the Funds, and may be deemed to have the power to vote or direct the vote of and the power to dispose or direct the disposition of such securities. Julian C. Baker and Felix J. Baker are also the sole partners of FBB, a general partnership, and as such may be deemed to be beneficial owners of shares of common stock directly held by FBB and may be deemed to have the power to vote or direct the vote and dispose or direct the disposition of those shares.

The Reporting Persons disclaim beneficial ownership of the securities directly held by each of the Funds, and this Amendment No. 41 shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 13(d) or for any other purpose.

Julian C. Baker and Felix J. Baker are Directors of the Issuer. Julian C. Baker serves as the Chair of the Nominating and Corporate Governance Committee and Felix J. Baker serves as the Chair of the Compensation Committee and serves on the Science & Technology Committee of the Issuer's Board.

On April 1, 2019, Felix J. Baker and Julian C. Baker each received 149 shares of restricted stock of the Issuer ("Restricted Stock") pursuant to the Issuer's 2005 Stock Incentive Plan in lieu of \$10,000 in director retainer fees, respectively. The shares of Restricted Stock are fully vested.

Page 8 of 13 Pages

Felix J. Baker and Julian C. Baker serve on the Issuer's Board as representatives of the Funds. Due to the agreements and policies of the Funds, Felix J. Baker and Julian C. Baker do not have any right to receive any profits from any securities received as compensation for serving as Directors of the Issuer and therefore have no pecuniary interest in the common stock, Restricted Stock or options to purchase common stock of the Issuer ("Stock Options") received by Felix J. Baker or Julian C. Baker as director compensation. Certain of the Funds are entitled to the pecuniary interest in such common stock, Restricted Stock and Stock Options as each holds an indirect pecuniary interest. Felix J. Baker and Julian C. Baker, solely as a result of their ownership interest in the general partners of the general partners of the Funds, may be deemed to have an indirect pecuniary interest in such common stock, Restricted Stock and Stock Options (i.e. no direct pecuniary interest).

The Adviser has voting and investment power over the common stock, Restricted Stock and Stock Options held by Julian C. Baker and Felix J. Baker received as director compensation. The Adviser GP, and Felix J. Baker and Julian C. Baker as managing members of the Adviser GP, may be deemed to have the power to vote or direct the vote of and the power to dispose or direct the disposition of such common stock, Restricted Stock and Stock Options held by Julian C. Baker and Felix J. Baker received as director compensation.

(c) The following transactions in the common stock of the Issuer were effected by the Funds noted below during the eighteen days preceding the filing of this statement. The transactions in common stock effected the nineteenth to sixtieth days are disclosed on the previous Schedules 13D filed on March 14, 2019 and February 28, 2019. All transactions were effected in the over-the-counter market directly with a broker-dealer. Except as disclosed herein or in any previous amendments to this Schedule 13D, none of the Reporting Persons or their affiliates has effected any other transactions in securities of the Issuer during the past 60 days.

Edgar Filing: GENOMIC HEALTH INC - Form SC 13D/A

Name	Date	Number of Shares	Transaction	Price/Share	Footnotes
Baker/Tisch Investments, L.P.	4/3/2019	1,374	Sale	68.8988	1
Baker Bros. Investments II, L.P.	4/3/2019	93	Sale	68.8988	1
Baker Bros. Investments, L.P.	4/3/2019	1,230	Sale	68.8988	1
14159, L.P.	4/3/2019	2,121	Sale	68.8988	1
667, L.P.	4/3/2019	12,305	Sale	68.8988	1
Baker Brothers Life Sciences, L.P.	4/3/2019	80,146	Sale	68.8988	1
Baker/Tisch Investments, L.P.	4/4/2019	1,145	Sale	66.6396	2
Baker Bros. Investments II, L.P.	4/4/2019	78	Sale	66.6396	2
Baker Bros. Investments, L.P.	4/4/2019	1,025	Sale	66.6396	2
14159, L.P.	4/4/2019	1,768	Sale	66.6396	2
667, L.P.	4/4/2019	10,253	Sale	66.6396	2
Baker Brothers Life Sciences, L.P.	4/4/2019	66,784	Sale	66.6396	2
Baker/Tisch Investments, L.P.	4/5/2019	362	Sale	68.6279	2
Baker Bros. Investments II, L.P.	4/5/2019	25	Sale	68.6279	3
Baker Bros. Investments, L.P.	4/5/2019	324	Sale	68.6279	3
14159, L.P.	4/5/2019	559	Sale	68.6279	3
667, L.P.	4/5/2019	3,242	Sale	68.6279	3
Baker Brothers Life Sciences, L.P.	4/5/2019	21,116	Sale	68.6279	3
Baker/Tisch Investments, L.P.	4/5/2019	734	Sale	68.7159	3
Baker Bros. Investments II, L.P.	4/5/2019	50	Sale	68.7159	4
Baker Bros. Investments, L.P.	4/5/2019	658	Sale	68.7159	4
14159, L.P.	4/5/2019	1,134	Sale	68.7159	4
667, L.P.	4/5/2019	6,581	Sale	68.7159	4
Baker Brothers Life Sciences, L.P.	4/5/2019	42,863	Sale	68.7159	4
Baker/Tisch Investments, L.P.	4/8/2019	320	Sale	67.8965	4
Baker Bros. Investments II, L.P.	4/8/2019	22	Sale	67.8965	5
Baker Bros. Investments, L.P.	4/8/2019	286	Sale	67.8965	5
14159, L.P.	4/8/2019	494	Sale	67.8965	5
667, L.P.	4/8/2019	2,865	Sale	67.8965	5
Baker Brothers Life Sciences, L.P.	4/8/2019	18,661	Sale	67.8965	5
Baker/Tisch Investments, L.P.	4/9/2019	31	Sale	67.8692	5
Baker Bros. Investments II, L.P.	4/9/2019	2	Sale	67.8692	6
Baker Bros. Investments, L.P.	4/9/2019	28	Sale	67.8692	6
14159, L.P.	4/9/2019	48	Sale	67.8692	6
667, L.P.	4/9/2019	278	Sale	67.8692	6
Baker Brothers Life Sciences, L.P.	4/9/2019	1,813	Sale	67.8692	6
Baker/Tisch Investments, L.P.	4/9/2019	266	Sale	67.6760	7
Baker Bros. Investments II, L.P.	4/9/2019	18	Sale	67.6760	7
Baker Bros. Investments, L.P.	4/9/2019	239	Sale	67.6760	7
14159, L.P.	4/9/2019	411	Sale	67.6760	7
667, L.P.	4/9/2019	2,386	Sale	67.6760	7
Baker Brothers Life Sciences, L.P.	4/9/2019	15,543	Sale	67.6760	7
Baker/Tisch Investments, L.P.	4/10/2019	1,758	Sale	68.7006	8
Baker Bros. Investments II, L.P.	4/10/2019	120	Sale	68.7006	8

## Edgar Filing: GENOMIC HEALTH INC - Form SC 13D/A

Baker Bros. Investments, L.P.	4/10/2019	1,575	Sale	68.7006	8
14159, L.P.	4/10/2019	2,716	Sale	68.7006	8
667, L.P.	4/10/2019	15,755	Sale	68.7006	8
Baker Brothers Life Sciences, L.P.	4/10/2019	102,618	Sale	68.7006	8
Baker/Tisch Investments, L.P.	4/10/2019	185	Sale	69.1225	9
Baker Bros. Investments II, L.P.	4/10/2019	13	Sale	69.1225	9
Baker Bros. Investments, L.P.	4/10/2019	166	Sale	69.1225	9
14159, L.P.	4/10/2019	287	Sale	69.1225	9
667, L.P.	4/10/2019	1,663	Sale	69.1225	9
Baker Brothers Life Sciences, L.P.	4/10/2019	10,832	Sale	69.1225	9
Baker/Tisch Investments, L.P.	4/11/2019	1,039	Sale	67.4208	10
Baker Bros. Investments II, L.P.	4/11/2019	71	Sale	67.4208	10
Baker Bros. Investments, L.P.	4/11/2019	930	Sale	67.4208	10
14159, L.P.	4/11/2019	1,604	Sale	67.4208	10
667, L.P.	4/11/2019	9,307	Sale	67.4208	10
Baker Brothers Life Sciences, L.P.	4/11/2019	60,618	Sale	67.4208	10
Baker/Tisch Investments, L.P.	4/11/2019	1,817	Sale	66.6074	11
Baker Bros. Investments II, L.P.	4/11/2019	124	Sale	66.6074	11
Baker Bros. Investments, L.P.	4/11/2019	1,628	Sale	66.6074	11
14159, L.P.	4/11/2019	2,807	Sale	66.6074	11
667, L.P.	4/11/2019	16,282	Sale	66.6074	11
Baker Brothers Life Sciences, L.P.	4/11/2019	106,054	Sale	66.6074	11
Baker/Tisch Investments, L.P.	4/12/2019	2,966	Sale	64.6197	12
Baker Bros. Investments II, L.P.	4/12/2019	202	Sale	64.6197	12
Baker Bros. Investments, L.P.	4/12/2019	2,656	Sale	64.6197	12
14159, L.P.	4/12/2019	4,581	Sale	64.6197	12
667, L.P.	4/12/2019	26,575	Sale	64.6197	12
Baker Brothers Life Sciences, L.P.	4/12/2019	173,085	Sale	64.6197	12
Baker/Tisch Investments, L.P.	4/12/2019	1,093	Sale	67.1294	13
Baker Bros. Investments II, L.P.	4/12/2019	74	Sale	67.1294	13
Baker Bros. Investments, L.P.	4/12/2019	979	Sale	67.1294	13
14159, L.P.	4/12/2019	1,688	Sale	67.1294	13
667, L.P.	4/12/2019	9,791	Sale	67.1294	13
Baker Brothers Life Sciences, L.P.	4/12/2019	63,775	Sale	67.1294	13
Baker/Tisch Investments, L.P.	4/12/2019	158	Sale	65.3239	14
Baker Bros. Investments II, L.P.	4/12/2019	11	Sale	65.3239	14
Baker Bros. Investments, L.P.	4/12/2019	142	Sale	65.3239	14
14159, L.P.	4/12/2019	244	Sale	65.3239	14
667, L.P.	4/12/2019	1,417	Sale	65.3239	14
Baker Brothers Life Sciences, L.P.	4/12/2019	9,232	Sale	65.3239	14



(1) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$68.60 to \$69.53. The Reporting Persons undertake to provide the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(2) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$66.50 to \$67.20. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(3) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$68.31 to \$69.05. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(4) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$68.60 to \$69.25. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(5) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$67.88 to \$68.11. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(6) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$67.25 to \$68.00. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(7) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$67.55 to \$68.01. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(8) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$68.53 to \$69.50. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(9) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$69.00 to \$69.43. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(10)

The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$66.92 to \$67.85. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging (11) from \$66.60 to \$66.82. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging (12) from \$ 64.60 to \$65.15. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging (13) from \$66.63 to \$67.44. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging (14) from \$65.15 to \$66.15. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(d) Certain securities of the Issuer are held directly by 667, a limited partnership the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole general partner of which is Baker Biotech Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members of Baker Biotech Capital (GP), LLC.

Certain securities of the Issuer are held directly by Life Sciences, a limited partnership the sole general partner of which is Baker Brothers Life Sciences Capital, L.P., a limited partnership the sole general partner of which is Baker Brothers Life Sciences Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members of Baker Brothers Life Sciences Capital (GP), LLC.

Certain securities of the Issuer are held directly by 14159, a limited partnership the sole general partner of which is 14159 Capital, L.P., a limited partnership the sole general partner of which is 14159 Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members of 14159 Capital (GP), LLC.

Certain securities of the Issuer are held directly by FBB, a general partnership of which the sole partners are Julian C. Baker and Felix J. Baker.

Certain securities of the Issuer are held directly by Baker Bros. Investments, a limited partnership the sole general partner of which is Baker Bros. Capital, L.P., a limited partnership the sole general partner of which is Baker Bros.

Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members of Baker Bros. Capital (GP), LLC.

Certain securities of the Issuer are held directly by Baker Bros. Investments II, a limited partnership the sole general partner of which is Baker Bros. Capital, L.P., a limited partnership the sole general partner of which is Baker Bros. Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members of Baker Bros. Capital (GP), LLC.

Certain securities of the Issuer are held directly by Baker Tisch, a limited partnership the sole general partner of which is Baker/Tisch Capital, L.P., a limited partnership the sole general partner of which is Baker/Tisch Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members of Baker/Tisch Capital (GP), LLC.

(e) Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

April 12, 2019

**BAKER BROS.  
ADVISORS LP**

By: Baker Bros. Advisors  
(GP) LLC, its general  
partner

By: /s/ Scott L. Lessing  
Name: Scott L. Lessing  
Title: President

**BAKER BROS.  
ADVISORS (GP) LLC**

By: /s/ Scott L. Lessing  
Name: Scott L. Lessing  
Title: President

/s/ Julian C. Baker  
Julian C. Baker

/s/ Felix J. Baker  
Felix J. Baker

**FBB Associates**

By: /s/ Julian C. Baker  
Name: Julian C. Baker  
Title: Partner

